# Safety and Efficacy of Asimadoline (TP0052) in Patients With Vasomotor Symptoms (VMS).

> **NCT07042516** · PHASE2 · RECRUITING · sponsor: **Tioga Pharmaceuticals** · enrollment: 120 (estimated)

## Conditions studied

- Vasomotor Symptoms

## Interventions

- **DRUG:** Asimadoline

## Key facts

- **NCT ID:** NCT07042516
- **Lead sponsor:** Tioga Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-13
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-02-20
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2025-09-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07042516

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07042516, "Safety and Efficacy of Asimadoline (TP0052) in Patients With Vasomotor Symptoms (VMS).". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07042516. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*